English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT
  Pharmacological and phosphoproteomic approaches to roles of protein kinase C in kappa opioid receptor-mediated effects in mice.

Liu, J. J., Chiu, Y.-T., Chen, C., Huang, P., Mann, M., & Liu-Chen, L.-Y. (2020). Pharmacological and phosphoproteomic approaches to roles of protein kinase C in kappa opioid receptor-mediated effects in mice. Neuropharmacology, 181: 108324. doi:10.1016/j.neuropharm.2020.108324.

Item is

Basic

show hide
Genre: Journal Article

Files

show Files

Locators

show

Creators

show
hide
 Creators:
Liu, Jeffrey J.1, Author              
Chiu, Yi-Ting2, Author
Chen, Chongguang2, Author
Huang, Peng2, Author
Mann, Matthias1, Author              
Liu-Chen, Lee-Yuan2, Author
Affiliations:
1Mann, Matthias / Proteomics and Signal Transduction, Max Planck Institute of Biochemistry, Max Planck Society, ou_1565159              
2external, ou_persistent22              

Content

show
hide
Free keywords: Phosphoproteomics; Protein kinase C; Wnt; mTOR and CB1; kappa opioid receptor
 Abstract: Kappa opioid receptor (KOR) agonists possess adverse dysphoric and psychotomimetic effects, thus limiting their applications as non-addictive anti-pruritic and analgesic agents. Here, we showed that protein kinase C (PKC) inhibition preserved the beneficial antinociceptive and antipruritic effects of KOR agonists, but attenuated the adverse condition placed aversion (CPA), sedation, and motor incoordination in mice. Using a large-scale mass spectrometry-based phosphoproteomics of KOR-mediated signaling in the mouse brain, we observed PKC-dependent modulation of G protein-coupled receptor kinases and Wnt pathways at 5 min; stress signaling, cytoskeleton, mTOR signaling and receptor phosphorylation, including cannabinoid receptor CB1 at 30 min. We further demonstrated that inhibition of CB1 attenuated KOR-mediated CPA. Our results demonstrated the feasibility of in vivo biochemical dissection of signaling pathways that lead to side effects. Copyright © 2020. Published by Elsevier Ltd.

Details

show
hide
Language(s): eng - English
 Dates: 2020-092020-12
 Publication Status: Published in print
 Pages: -
 Publishing info: -
 Table of Contents: -
 Rev. Type: Peer
 Identifiers: ISI: 32976891
DOI: 10.1016/j.neuropharm.2020.108324
 Degree: -

Event

show

Legal Case

show

Project information

show

Source 1

show
hide
Title: Neuropharmacology
  Other : Neuropharmacol.
Source Genre: Journal
 Creator(s):
Affiliations:
Publ. Info: Amsterdam [etc.] : Pergamon
Pages: - Volume / Issue: 181 Sequence Number: 108324 Start / End Page: - Identifier: ISSN: 0028-3908
CoNE: https://pure.mpg.de/cone/journals/resource/954925428257